UNION therapeutics to present orismilast Phase 2b results in atopic dermatitis as a late-breaking oral presentation at the EADV Congress 2024

UNION therapeutics Denmark

ADESOS Phase 2b results with orismilast in atopic dermatitis (AD) selected as late-breaking oral presentationAdditionally, two posters on data from the pioneering use of tape stripping for biomarker analysis in the ADESOS study and additional ADESOS Phase 2b resultsOrismilast is a next generation, high potency PDE4 B/D selective inhibitor with reported positive results from a Phase 2b study in psoriasis and Phase 2, IIT, study in hidradenitis suppurativa (HS); orismilast is currently being evaluated in an ongoing Phase 2, IIT study in ulcerative colitis (UC)UNION plan to progress orismilast to Phase 3 development in AD&
Silverberg J.I. et al., JEADV 2022: https://onlinelibrary.wiley.com/doi/10.1111/jdv.18818  &
Warren R.B. et al., JEADV 2022: https://onlinelibrary.wiley.com/doi/10.1111/jdv.18812

Contacts
Morten Boesen, Chief Financial Officer, UNION therapeutics A/S
[phone]
[e-mail]

Sarah Toft-Jørgensen, Director of Communications and IR, UNION therapeutics A/S
[phone]
[e-mail]

About UNION therapeutics

UNION therapeutics is a privately held, clinical stage, pharmaceutical development company focused on immunology. UNION's lead asset is orismilast, a next generation, high potency PDE4 B/D inhibitor, for a range of immunological diseases e.g., atopic dermatitis (AD) and hidradenitis suppurativa. Orismilast holds the potential to become the first safe oral treatment in AD. UNION is headquartered in Hellerup, Denmark, and led by an international team combining biotech entrepreneurs and seasoned pharma executives, with a track record of developing and launching more than fifteen marketed drugs. Read more at www.uniontherapeutics.com 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/union-therapeutics/r/union-therapeutics-to-present-orismilast-phase-2b-results-in-atopic-dermatitis-as-a-late-breaking-or,c4040268

 

View original content:https://www.prnewswire.co.uk/news-releases/union-therapeutics-to-present-orismilast-phase-2b-results-in-atopic-dermatitis-as-a-late-breaking-oral-presentation-at-the-eadv-congress-2024-302254060.html